Clinical trials: Hypertension, Pulmonary Arterial
Pulmonary Arterial Hypertension
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus background PAH therapy) on…
- Trial name
- HYPERION (NCT04811092)
- Testing
- Sotatercept
- Where
- 152 sites in United States, Argentina and 25 more
- Volunteers
- 321 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension, Pulmonary
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- PATENT-2 (NCT00863681)
- Testing
- Riociguat (BAY63-2521)
- Where
- 99 sites in United States, Argentina and 25 more
- Volunteers
- 396 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH
The aim of the study is to document the left and right ventricular function in patients with sclerodermia associated pulmonal arterial hypertension via 3D echocardiography.
- Trial name
- EVA3D (NCT02207868)
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Regina Steringer-Mascherbauer
Reperfusion Pulmonary Edema
Evaluation of the Effectiveness of Non-invasive Ventilation on the Reperfusion Pulmonary Edema Post Pulmonary Artery Angioplasty in the Post Embolic Pulmonary Hypertension
The purpose of this study is to determine whether Non Invasive Ventilation are effective in prevention of reperfusion pulmonary edema after pulmonary artery angioplasty.
- Trial name
- OPR_VNI (NCT02548091)
- Testing
- Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10), Non invasive ventilation, monitoring system Pulse-Induced Contour Cardiac Output (Picco)
- Where
- France
- Volunteers
- 236 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Arterial Hypertension
Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate patterns of metabolic activity in the heart of patients with pulmonary arterial hypertension(PAH).
- Trial name
- RVMET (NCT01572077)
- Testing
- FTHA, FDG PET imaging.
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Sickle Cell Disease, Dyslipidemia
Lipid Balance in Adult Sickle Cell Patients
This study aims to describe and/or searches for, in cohorts of adult sickle cell anemia (SCA) and SC sickle cell patients living in the French West Indies and followed by SCD Reference and Competence Centers: 1-lipids profiles…
- Conditions
- Sickle Cell Disease, Dyslipidemia, Complication
- Trial name
- HDL2 (NCT05780775)
- Testing
- HDL2
- Where
- Guadeloupe
- Volunteers
- 116 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Pulmonary Arterial Hypertension
Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain
Treprostinil subcutaneous (under the skin) infusion is a very good medication for treating pulmonary arterial hypertension but infusion site pain may be very severe in some patients.
- Trial name
- NCT01433328
- Testing
- Lidocaine
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Jewish General Hospital
Pulmonary Arterial Hypertension
Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study
The study will recruit and follow up patients for five years patients newly diagnosed with congenital heart disease associated pulmonary arterial hypertension(CHD-PAH) from the investigator's hospital.
- Trial name
- CHD-PAHCS (NCT03977428)
- Testing
- standard of care
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Exercise-induced Pulmonary Arterial Hypertension
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
The purpose of this study is assess whether ambrisentan can help people with exercise- induced pulmonary arterial hypertension (EIPAH).
- Trial name
- EiPAH (NCT01338636)
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Arterial Hypertension
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
- Trial name
- GRIPHON (NCT01106014)
- Testing
- Selexipag
- Where
- 182 sites in United States, Argentina and 37 more
- Volunteers
- 1,156 people
- Sponsor
- Actelion
Pulmonary Hypertension
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
This Phase 2 study was to determine the incidence of increased serum aminotransferase concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as well as the overall safety and tolerability of…
- Trial name
- NCT00423592
- Testing
- ambrisentan
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in…
- Trial name
- PAH (NCT03926793)
- Testing
- GB002, Generic Dry Powder Inhaler
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Intrahepatic Bile Duct Cancer, Intrahepatic Cholangiocarcinoma (Icc)
Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery
The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery.
- Conditions
- Intrahepatic Bile Duct Cancer, Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- PUMP IV (NCT06888063)
- Testing
- Hepatic Arterial Infusion Pump chemotherapy with floxuridin
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Erasmus Medical Center
Pulmonary Arterial Hypertension
Pulmonary Hypertension and Anastrozole Trial
The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in…
- Trial name
- PHANTOM (NCT03229499)
- Testing
- Anastrozole
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH).
- Trial name
- NCT00439946
- Testing
- treprostinil, Crono Five ambulatory pump
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH), Exercise Therapy
PAH Exercise Study
Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as…
- Trial name
- NCT06941441
- Testing
- Home exercise program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Pulmonary Hypertension
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00323024
- Testing
- NX1011
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- NITROX, LLC
Pulmonary Arterial Hypertension
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with…
- Trial name
- TOMORROW (NCT02932410)
- Testing
- Macitentan, Standard-of-care
- Where
- 85 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- Actelion
Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH)
Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
The goal of this observational pilot trial is to evaluate the feasibility of home monitoring for patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).
- Conditions
- Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH), Home Monitoring Follow-up
- Trial name
- Nor-SScCare (NCT06865118)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
This is a multicenter, single-arm trial to evaluate the safety of the transition from Selexipag to Remodulin® then Oral Treprostinil in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT03016468
- Testing
- Parenteral Remodulin (treprostinil) injection, Oral Treprostinil
- Sponsor
- United Therapeutics